HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OTC Homeopathic Labels Must Include Scientific Disclaimers – FTC

This article was originally published in The Pink Sheet

Executive Summary

US trade regulator will require an "inherent contradiction" for homeopathic OTC labels: disclaimers to FDA-compliant label indications indicating a lack of scientific evidence that the product works.

You may also be interested in...



Avadim Adamant Its Support For Homeopathic Topical Ad Claims Meets FTC Standards

Avadim Health could get FTC scrutiny after it declines to comply with two findings by an industry self-regulation group to discontinue 26 claims for its Theraworx Relief homeopathic products. It says the analysis “misapplied the well-recognized standards of substantiation” established by FTC. 

FTC Homeopathic Advertising Review Spurs Broader Disclaimer Suggestion, Opens New Stage For RCT Debate

FTC attorneys say homeopathic claims should meet the same standard of proof the commission contends is required for dietary supplement advertising – randomized, controlled clinical trials. An industry groups says 92%-99% of participants in its study understood FDA does not review homeopathic drug label claims.

Naloxone Switch: Door Opener For Other NDAs That Swing On Consumer Education

Health care professionals provide naloxone in an outpatient setting in “highly successful programs,” but FDA approval of a switch rests on whether “just putting the drug on the store shelf for anyone to purchase with no training or guidance on use” will be safe, says nonprescription drug division head Theresa Michele.

Related Content

Topics

UsernamePublicRestriction

Register

RS123157

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel